A Study in Korea of Entecavir Versus Lamivudine in Adults With Chronic Hepatitis B Infection
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
Entecavir, 0.5 mg daily, will have clinical efficacy (assessed as an undetectable hepatitis B
DNA, <300 copies/mL, by Roche Comprehensive Bio-Analytical System Amplicor polymerase chain
reaction assay) that is comparable (noninferior) and potentially superior to lamivudine, 100
mg once daily, in adults with hepatitis B e antigen-negative chronic hepatitis B virus
infection.